Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 7
Submit an article Journal homepage
363
Views
10
CrossRef citations to date
0
Altmetric
Original Articles

A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome

Gail J. Roboza Department of Medicine, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USACorrespondence[email protected]
,
Pinkal Desaia Department of Medicine, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA
,
Sangmin Leea Department of Medicine, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA
,
Ellen K. Ritchiea Department of Medicine, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA
,
Eric S. Winerb Dana-Farber Cancer Institute, Boston, MA, USA
,
Mark DeMarioc Roche Pharma Research and Early Development, Roche Innovation Center New York, New York, NY, USA
,
Barbara Brennanc Roche Pharma Research and Early Development, Roche Innovation Center New York, New York, NY, USA
,
Eveline Nüeschd Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
,
Evelyne Chesned Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
,
Laura Brennanc Roche Pharma Research and Early Development, Roche Innovation Center New York, New York, NY, USA
,
Katharina Lechnerd Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
,
Martin Kornackerd Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
&
Daniel J. DeAngelob Dana-Farber Cancer Institute, Boston, MA, USA
 show all
Pages 1740-1748 | Received 01 Nov 2020, Accepted 21 Jan 2021, Published online: 13 Feb 2021

References

  • Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31:27–36.
  • Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017;28:1776–1787.
  • Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067–1073.
  • Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13:337–356.
  • Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524–528.
  • Groschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157:369–381.
  • Herrmann H, Blatt K, Shi J, et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget. 2012;3:1588–1599.
  • Chen C, Liu Y, Lu C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 2013;27:1974–1985.
  • Chen C, Liu Y, Rappaport AR, et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell. 2014;25:652–665.
  • Fiskus W, Sharma S, Qi J, et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther. 2014;13:1142–1154.
  • Stewart HJ, Horne GA, Bastow S, et al. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Med. 2013;2:826–835.
  • Shapiro GI, LoRusso PM, Dowlati A, et al. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Brit J Cancer. 2020.
  • Cheson BD, Bennett JM, Kopecky KJ, et al., International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the international working group for diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–4649.
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425.
  • Genta S, Pirosa MC, Stathis A. BET and EZH2 inhibitors: novel approaches for targeting cancer. Curr Oncol Rep. 2019;21:13.
  • Reyes-Garau D, Ribeiro ML, Roué G. Pharmacological targeting of BET bromodomain proteins in acute myeloid leukemia and malignant lymphomas: from molecular characterization to clinical applications. Cancers (Basel). 2019;11:E1483.
  • Cochran AG, Conery AR, Sims RJ. Bromodomains: a new target class for drug development. Nat Rev Drug Discov. 2019;18:609–628.
  • Berthon C, Raffoux E, Thomas X, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016;3:e186–e195.
  • Patel MR, Garcia-Manero G, Paquette R, et al. Phase 1 dose escalation and expansion study to determine safety, tolerability, pharmacokinetics, and pharmacodynamics of the BET inhibitor FT-1101 as a single agent in patients with relapsed or refractory hematologic malignancies. Blood. 2019;134:3907.
  • Pemmaraju N, Borate U, Solh M, et al. Dose escalation study of BET inhibitor PLX2853 in patients with relapsed or refractory acute myeloid leukemia or high risk myelodysplastic syndrome. Blood. 2019;134:1391.
  • Dawson M, Stein EM, Huntly BLP, et al. A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from Part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML). Blood. 2017;130:1377.
  • Fiskus W, Cai T, DiNardo CD, et al. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019;9:4.
  • Bui MH, Lin X, Albert DH, et al. Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies. Cancer Res. 2017;77:2976–2989.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.